Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder
阿立哌唑长期维持治疗与自闭症相关的易激惹儿科患者的安全性和有效性
The purpose of this study is to determine whether pediatric participants with irritability associated with autistic disorder who have responded to aripiprazole treatment will experience a relapse significantly later when continuing therapy with aripiprazole than will participants who receive placebo.
研究概览
研究类型
注册 (实际的)
阶段
- 第四阶段
联系人和位置
学习地点
-
-
Alabama
-
Dothan、Alabama、美国、36303
- Harmonex Neuroscience Research, Inc
-
-
Arizona
-
Phoenix、Arizona、美国、85006
- Southwest Autism Research And Resource Center
-
-
California
-
Costa Mesa、California、美国、92626
- Clinical Innovations, Inc.
-
Glendale、California、美国、91206
- Behavioral Research Specialists, Llc
-
Palo Alto、California、美国、94306
- Abbey Neuropsychology Clinic
-
San Francisco、California、美国、94143
- Ucsf - Lppi
-
Stanford、California、美国、94305
- Stanford University School Of Medicine
-
-
District of Columbia
-
Washington D.C.、District of Columbia、美国、20010
- Children'S National Medical Center
-
-
Florida
-
Gainesville、Florida、美国、32607
- Sarkis Clinical Trials
-
Hialeah、Florida、美国、33012
- Palm Springs Research Institute
-
Maitland、Florida、美国、32751
- Florida Clinical Research Center, Llc
-
Miami、Florida、美国、33155
- Miami Children'S Hospital
-
Tampa、Florida、美国、33613
- University Of South Florida
-
-
Georgia
-
Smyrna、Georgia、美国、30080
- Institute For Behavioral Medicine, Llc
-
-
Idaho
-
Coeur d'Alene、Idaho、美国、83814
- Kootenai Behavioral Health Center
-
-
Kentucky
-
Louisville、Kentucky、美国、40202
- Kosair Charities Pediatric Clinical Research Unit
-
-
Louisiana
-
Shreveport、Louisiana、美国、71103
- Lsu Health Sciences Center
-
-
Massachusetts
-
Newton、Massachusetts、美国、02459
- Neurocare, Inc.
-
-
Michigan
-
Bloomfield Hills、Michigan、美国、48302
- Neurobehavioral Medicine Group
-
-
Nevada
-
Las Vegas、Nevada、美国、89128
- Center For Psychiatry And Behavioral Medicine, Inc
-
-
New Jersey
-
Gibbsboro、New Jersey、美国、08026
- Clinical Research Center Of New Jersey
-
Toms River、New Jersey、美国、08755
- Children'S Specialized Hosp
-
-
New York
-
Stony Brook、New York、美国、11794
- Stony Brook University School Of Medicine
-
-
North Carolina
-
Chapel Hill、North Carolina、美国、27517
- Unc Chapel Hill
-
-
Ohio
-
Cleveland、Ohio、美国、44106
- University Hospitals Case Medical Center
-
Cleveland、Ohio、美国、44104
- Cleveland Clinic
-
Columbus、Ohio、美国、43210
- The Ohio State University Nisonger Center
-
-
Oklahoma
-
Oklahoma City、Oklahoma、美国、73116
- Cutting Edge Research Group
-
Oklahoma City、Oklahoma、美国、73117
- Ou Physician'S Child Study Center
-
Tulsa、Oklahoma、美国、74104
- Tulsa Clinical Research, Llc
-
-
Oregon
-
Gresham、Oregon、美国、97030
- Cyn3rgy Research
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19124
- Drexel University College Of Medicine
-
Pittsburgh、Pennsylvania、美国、15203
- Western Psychiatric Institute And Clinic
-
-
Tennessee
-
Kingsport、Tennessee、美国、37660
- Holston Medical Group
-
-
Texas
-
DeSoto、Texas、美国、75115
- Insite Clinical Research
-
-
Utah
-
Clinton、Utah、美国、84015
- Ericksen Research And Development
-
-
Virginia
-
Norfolk、Virginia、美国、23510
- Childrens Specialty Gr., Pllc
-
Richmond、Virginia、美国、23298
- Virginia Treatment Center For Children
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Key Inclusion Criteria:
- Male or female children or adolescents, 6 to 17 years of age, inclusive, at the time of the baseline visit
- Meets current diagnostic criteria of the Diagnostic and Statistical Manual-of Mental Disorders IV-Text Revised for autistic disorder and displays behaviors such as tantrums, aggression, self-injurious behavior, or a combination of these problems. Diagnosis of autistic disorder will be confirmed by the Autism Diagnostic Interview-Revised.
- Participant or designated guardian or caregiver is able to comprehend and satisfactorily comply with the protocol requirements, in the opinion of the investigator.
- Demonstrates behaviors such as tantrums, aggression, or self-injury or a combination of these problems
- An Aberrant Behavior Checklist Irritability subscale score ≥18 AND a Clinical Global Impressions Severity score ≥4 at the Screening and Baseline Visits.
- Mental age of at least 24 months
Key Exclusion Criteria:
- Treatment resistant to neuroleptic medication, based on lack of therapeutic response to 2 different neuroleptics after treatment for at least 3 weeks each.
- Previous treatment with aripiprazole for at least 3 weeks duration at an adequate daily dose, without demonstrating a clinically meaningful response.
- Lifetime diagnosis of bipolar disorder, psychosis, or schizophrenia, or a current diagnosis of major depressive disorder
- Diagnosis of Pervasive Developmental Disorder-Not Otherwise Specified, Asperger's Syndrome, Rett's Syndrome, childhood disintegrative disorder, or Fragile X Syndrome
- History of neuroleptic malignant syndrome
- At significant risk for suicide based on history or routine psychiatric status examination
- A seizure within the past year
- History of severe head trauma or stroke
- History or current evidence of any unstable medical conditions that would expose the patient to undue risk of a significant adverse event or interfere with assessments of safety or efficacy during the course of the trial
- Weight lower than 15 kg
- Known allergy or hypersensitivity to aripiprazole or other dihidrocarbostyrils
- History of a clinically significant low white blood cell count or a drug-induced leukopenia/neutropenia
- Any other medically significant abnormal laboratory test or vital sign result or electrocardiogram finding
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
安慰剂比较:安慰剂
|
Tablets, oral, 0 mg, once daily, 16 weeks |
|
实验性的:阿立哌唑
|
Tablets, oral, 2-15 mg, once daily, 13-42 weeks
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Percentage of Patients Relapsing by Week 16
大体时间:From end of Phase 1 (Date of randomization) to Week 16 of Phase 2 and end of treatment
|
Time of relapse=date when patient meets relapse criteria. There are 4 definitions for relapse: 1. Patient meets the following criteria for 2 consecutive visits: (a) Aberrant Behavior Checklist Irritability score ≥25% than score at end of Phase 1 AND (b) Clinical Global Impression Improvement scale rating of 'Much Worse' or 'Very Much Worse' relative to rating at end of Phase 1. If relapse criteria met at 1 visit, 2nd visit should occur in about 1 week to reevaluate whether relapse criteria are still met. 2. Patient discontinues for "Lost to Follow-up" after a visit in which he or she met Definition 1 criteria (a&b). 3. Patient begins a prohibited drug (whether a study investigator or outside source prescribed) to treat worsening symptoms of irritability of autistic disorder after a visit where patient met Definition 1 criteria (a&b). 4. Patient discontinues due to hospitalization for worsening symptoms of irritability or due to lack of efficacy based on investigator's assessment. |
From end of Phase 1 (Date of randomization) to Week 16 of Phase 2 and end of treatment
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Adjusted Mean Change From Baseline to Week 16 on the Aberrant Behavior Checklist Irritability (ABC-I) Subscale Score (Last Observation Carried Forward [LOCF])
大体时间:From Baseline (end of Phase 1) to Week 16 of Phase 2
|
ABC is an informant-based checklist used to assess and classify problem behaviors of children and adolescents with mental retardation. The 58 items are rated on a 4-point scale (0=not at all a problem to 3=the problem is severe in degree), and resolve into 5 subscales: 1) irritability, agitation; 2) lethargy, social withdrawal; 3) stereotypic behavior; 4) hyperactivity, noncompliance; and 5) inappropriate speech. The ABC can be completed by parents, special educators, psychologists, direct caregivers, nurses, and others knowing the participant. Psychometric assessment of the ABC indicates that its subscales have high internal consistency, adequate reliability, and established validity. The ABC-I Subscale Score ranges from 0 to 45, with a negative change in score signifying improvement. LOCF data set includes data recorded at a given visit or, if no observation was recorded at that visit, data carried forward from the prior visit. chg=change; BL=baseline; APR=aripiprazole; vs=versus. |
From Baseline (end of Phase 1) to Week 16 of Phase 2
|
|
Change From Baseline in Mean Clinical Global Impression Improvement (CGI-I) Scale Score at Week 16 (Last Observation Carried Forward [LOCF])
大体时间:From Baseline (end of Phase 1) to Week 16 of Phase 2
|
CG-I rating scale permits global evaluation of patient's improvement over time. At baseline (BL), CGI Severity of Illness assessment is performed, in which the clinician rates severity of patient's condition on a 7-point scale ranging from 1=no symptoms to 7=very severe symptoms. Higher total score=worse symptoms. At subsequent visits, clinician assesses patient's improvement relative to symptoms at baseline on CGI-I 7-point scale ranging from 1=very much improved to 7=very much worse. Since the drug targets irritability symptoms, the CGI focuses on severity of irritability secondary to autistic disorder. Lower score=more improved symptoms. LOCF data set includes data recorded at a given visit or, if nothing recorded, data areccarried forward from the prior visit. For secondary endpoints (endpt), hierarchical testing was used to keep overall experiment-wise type I error rate to <=0.05. diff=difference; IS=irritability scale; PA=primary analysis; signif=significance/significantly. |
From Baseline (end of Phase 1) to Week 16 of Phase 2
|
|
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Discontinuation During Phase 1
大体时间:Up to 26 weeks
|
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. |
Up to 26 weeks
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, and Treatment-related AEs During Phase 2
大体时间:Weekly from Weeks 1 through 16 (end of treatment) of Phase 2
|
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug. |
Weekly from Weeks 1 through 16 (end of treatment) of Phase 2
|
合作者和调查者
出版物和有用的链接
一般刊物
- Findling RL, Mankoski R, Timko K, Lears K, McCartney T, McQuade RD, Eudicone JM, Amatniek J, Marcus RN, Sheehan JJ. A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. J Clin Psychiatry. 2014 Jan;75(1):22-30. doi: 10.4088/jcp.13m08500.
- Iffland M, Livingstone N, Jorgensen M, Hazell P, Gillies D. Pharmacological intervention for irritability, aggression, and self-injury in autism spectrum disorder (ASD). Cochrane Database Syst Rev. 2023 Oct 9;10(10):CD011769. doi: 10.1002/14651858.CD011769.pub2.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.